Compare BJ & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BJ | KRYS |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 9.6B |
| IPO Year | 2018 | 2017 |
| Metric | BJ | KRYS |
|---|---|---|
| Price | $92.08 | $345.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $108.36 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.5M | 210.7K |
| Earning Date | 05-21-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.50 | ★ 128.00 |
| EPS | 2.46 | ★ 3.62 |
| Revenue | ★ $21,457,274,000.00 | $389,130,000.00 |
| Revenue This Year | $8.86 | $38.74 |
| Revenue Next Year | $6.50 | $32.53 |
| P/E Ratio | ★ $36.58 | $94.41 |
| Revenue Growth | 4.66 | ★ 33.94 |
| 52 Week Low | $83.21 | $159.24 |
| 52 Week High | $105.78 | $382.54 |
| Indicator | BJ | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 47.33 |
| Support Level | $89.26 | $331.79 |
| Resistance Level | $95.56 | $371.16 |
| Average True Range (ATR) | 2.01 | 10.53 |
| MACD | -0.14 | -1.05 |
| Stochastic Oscillator | 38.63 | 22.25 |
BJ's Wholesale Club, founded in 1984, operates a membership-based warehouse club model primarily along the US East Coast, with roughly 260 clubs and a growing domestic presence across 21 states. In fiscal 2025, the company generated over $21 billion in revenue. BJ's offers a value-oriented assortment skewed toward grocery, perishables, and consumables (72% of sales), general merchandise (11%), and gasoline (17%). Its business model is supported by recurring membership fee income and private-label brands such as Wellsley Farms and Berkley Jensen.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.